Brd4::Nutm1 fusion gene initiates NUT carcinoma in vivo
Life Science Alliance · 2024-07 · 7 (7) · e202402602
DOI: 10.26508/lsa.202402602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 09.05.2024. Verfasst von Dejin Zheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology and Reproductive Biology, College of Human Medicine, Michigan State University, East Lansing, MI, USA. Hauptthemen laut MEDLINE: Bromodomain Containing Proteins, Neoplasm Proteins, Nuclear Proteins, Oncogene Proteins, Fusion. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
NUT carcinoma (NC) is an aggressive cancer with no effective treatment. About 70% of NUT carcinoma is associated with chromosome translocation events that lead to the formation of a BRD4::NUTM1 fusion gene. Because the BRD4::NUTM1 gene is unequivocally cytotoxic when ectopically expressed in cell lines, questions remain on whether the fusion gene can initiate NC. Here, we report the first genetically engineered mouse model for NUT carcinoma that recapitulates the human t(15;19) chromosome translocation in mice. We demonstrated that the mouse t(2;17) syntenic chromosome translocation, forming the Brd4::Nutm1 fusion gene, could induce aggressive carcinomas in mice. The tumors present histopathological and molecular features similar to human NC, with enrichment of undifferentiated cells. Similar to the reports of human NC incidence, Brd4::Nutm1 can induce NC from a broad range of tissues with a strong phenotypical variability. The consistent induction of poorly differentiated carcinoma demonstrated a strong reprogramming activity of BRD4::NUTM1. The new mouse model provided a critical preclinical model for NC that will lead to better understanding and therapy development for NC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics, Gynecology and Reproductive Biology, College of Human Medicine, Michigan State University, East Lansing, MI, USA.
- Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI, USA.
- Home Institution: Department of Cytology and Histology, Faculty of Veterinary Medicine, Aswan University, Aswan, Egypt.
- Home Institution: Center for Reproductive Medicine and Department of Gynecology & Obstetrics, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, PR China.
- Infection Biology and Cancer Biology Program, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.
- City of Hope Comprehensive Cancer Center, Pathology, Duarte, CA, USA.
ORCID-Profile: Dejin Zheng, Ahmed A Elnegiry, Ehab Hanna, George I Mias, Mayra F Tsoi, Bin Gu
Förderung
- NCI NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Zheng, D., Elnegiry, A. A., Luo, C., Bendahou, M. A., Xie, L., Bell, D., Takahashi, Y., Hanna, E., Mias, G. I., Tsoi, M. F., & Gu, B. (2024). Brd4::Nutm1 fusion gene initiates NUT carcinoma in vivo. Life Science Alliance, 7(7), e202402602. https://doi.org/10.26508/lsa.202402602
Vancouver
Zheng D, Elnegiry AA, Luo C, Bendahou MA, Xie L, Bell D, et al. Brd4::Nutm1 fusion gene initiates NUT carcinoma in vivo. Life Science Alliance. 2024;7(7):e202402602. doi:10.26508/lsa.202402602
BibTeX
@article{Zheng2024,
author = {Zheng, Dejin and Elnegiry, Ahmed A and Luo, Chenxiang and Bendahou, Mohammed Amine and Xie, Liangqi and Bell, Diana and Takahashi, Yoko and Hanna, Ehab and Mias, George I and Tsoi, Mayra F and Gu, Bin},
title = {Brd4::Nutm1 fusion gene initiates NUT carcinoma in vivo},
journal = {Life Science Alliance},
year = {2024},
volume = {7},
number = {7},
pages = {e202402602},
doi = {10.26508/lsa.202402602}
}
EUVIMED